About International
Medical Instruments Inc.

Discoveries, Intellectual Property & Patent Protection

"IMI Healing Technologies is the developer and manufacturer of the superior efficacy LEP2000™ Photonic and Laser Therapy System and its modules used for pain treatment"
Dr. Natasha Salansky,
Photonic and Laser Therapy System
for Laser Therapy
Therapeutic Cold Lasers for Professionals

IMIHT is the developer and manufacturer of the Laser Therapy System

IMI Healing Technologies’ prime mission is to bring the recognition and use by medical communities in North America and around the Globe of its LEP2000™ Photonic and Laser Therapy System, and to offer high-efficacy therapeutic devices based on scientifically and clinically proven healing properties of multi-modality photonic and laser therapy approaches.

IMIHT is the world leader in therapeutic efficacy and versatility of the multi-modality LEP2000™ Photonic and Laser Therapy System and its modules

IMI Healing Technologies is the developer and manufacturer of the superior efficacy LEP2000™ Photonic and Laser Therapy System and its modules used for pain treatment, nerve regeneration, wound and tissue healing. IMI Healing Technologies (IMIHT) carries on research and development, and attends to the manufacture, distribution and servicing of LEP2000™ therapeutic lasers and cluster modules of light emitting diodes that feature high efficacy for a broad variety of medical applications.


After the invention of lasers in the late fifties, scientists discovered that laser emission could induce substantial photobiomodulation phenomena (alterations in DNA, ATP, protein synthesis, cell motility and proliferation, etc.). In the sixties, seventies, and eighties, initial clinical research explored the use of laser emission for clinical applications in Europe, the Soviet Union and Japan. Dr. E. Mester from Hungary, Dr. A. Rakcheev from the Soviet Union, and Dr. T. Ohshira from Japan obtained impressive clinical data on the clinical benefits of therapeutic lasers (low level lasers, cold lasers, low intensity or low energy lasers) for wound healing.

In the early eighties, Dr. Norman Salansky initiated research in Canada on photobiomodulation phenomena induced by therapeutic lasers. In parallel, Dr. Natasha Salansky (N. Filonenko) was conducting basic clinical surveys into healing mechanisms of therapeutic lasers and monochromatic light in the Soviet Union. At that time, many scientists believed that the essential properties of lasers - coherence and polarization - were necessary to induce photobiomodulation phenomena, and that non-coherent, non-polarized monochtromatic light sources could not induce photobiomodulation phenomena.

However, it was also known that Nobel Prize winner Dr. N. Finsen of Denmark had developed a successful treatment of small-pox skin marks with red non-coherent, non-polarized light in the 1890s much before the invention of lasers. Almost a century later in the early eighties, Dr. Norman Salansky conceived an idea to use clusters of non-coherent LEDs in visible and infrared spectrum along with therapeutic lasers for various clinical applications.

Using clusters of LEDs for therapeutic applications offered a lot of advantages: it provided full coverage of large areas that needed treatment, independent adjustability of important optical parameters and exploration of new optical parameters for treatment that were not available with lasers. In addition, the use of LEDs was more cost-effective as lasers were very expensive at that time.

In 1986, Dr. Norman Salansky created the first therapeutic device in Canada in which consecutive treatments with cluster modules of red light (660 nm) and cluster modules of infrared emission of 880 nm, combined with laser treatments of Nd:YA6 laser (1,064 nm) were used for clinical applications. Since then, this prototype of LEP2000™ has been continuously upgraded to provide higher therapeutic efficacy, greater versatility for medical applications, high reliability and user- friendliness for clinicians.

Novel Concepts of Photonic and Laser Therapy
Discovery of Therapeutic Optical Windows
Discovery of Multiple Optical Parameters that Define Effectiveness of TOWs

3D Photon Distribution is Critical for
High Efficacy of Photonic & Laser Therapy

A laser is essentially a narrow beam of coherent monochromatic light and typically covers a small skin area unless it is defocused by a lens. This represents substantial difficulty for the treatment of large areas of injured tissues (a large wound, back, shoulder, etc). An additional difficulty of therapeutic lasers is that unlike LEDs it is not easy to control independently all the essential laser parameters (power, irradiance, frequency, duty cycle, etc). The introduction by Dr. Norman Salansky in the eighties of cluster probes of LEDs including flexible probes substantially expanded treatment efficacy and versatility of photonic and laser therapy making possible treatment for a variety of diseases, stages of diseases, and areas to be treated.

Drs. Salansky Clinical Protocols of Photonic & Laser Therapy

Multi-Modality Therapy with LEP2000™ vs Monotherapy with Low Level Lasers Represents a Shift in Treatment Paradigm

As one can understand from the above brief description of Drs. Salansky approach to Photonic and Laser Therapy, it represents a new paradigm in the following aspects: 1) While a single set of optical parameters (TOW) being optimized may produce a beneficial therapeutic effect, multiple TOWs (with different wavelengths and different sets of optical parameters) have to be applied in physiologically justified sequence in order to achieve greater integrative therapeutic effect for a given disease. 2) Therefore, we see here a shift of paradigm from low level laser (low intensity or low energy laser) therapy – monotherapy - to more effective Photonic and Laser Therapy LEP2000™ - multimodality therapy. 3) Another shift in paradigm is related to the optimization of optical parameters of lasers and clusters of LEDs. While everybody in this field recognizes the need for some optical parameter optimization, many still believe that simply making the right selection of wavelength (nm), power (mW), and dose (J/cm2) will result in high-efficacy treatment for a given disease. Drs. Salansky approach requires the optimization of a whole set of optical parameters (TOW) and 3D photon distribution within abnormal or injured tissue in order to improve the specific pathological condition of that tissue.

Summary of IMI Inventions Reflected In IMI Patents
Additional Advantages of IMI Technology
1px 1px 1px 1px